Ultragenyx制药 RARE 深 沪
等待开盘 10-07 09:30:00 美东时间
30.19
-1.020
-3.27%
华盛通- 最 高31.70
- 今 开31.42
- 成交量 132.02万股
- 最 低 30.15
- 昨 收 31.21
- 总市值 29.09亿
- 52周最高 57.995
- 市盈率 静 --
- 换手率 1.37%
- 52周最低 25.81
- 委 比 65.99%
- 总股本 9637.16万
- 历史最高 179.647
- 量 比 0.77
- 振 幅 4.97%
- 历史最低 25.81
- 每 手 1
- 风险率 7.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多聚焦肺癌、心血管疾病治疗，这些创新药将在第八届进博会首秀
10月5日，第八届进博会迎来开幕倒计时30天。多家全球领先的跨国药企和医药展商率先揭晓了将要亮相本届进博会的首秀展品和最新解决方案。 此前，进博局方面介绍，第八...
10-05 09:51
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
Ultragenyx Pharmaceutical Inc. has appointed Eric Olson as Chief Business Officer (CBO) and Executive Vice President, succeeding Thomas Kassberg's retirement. Olson will oversee business development, corporate development, and alliance management. With nearly 20 years of experience in biopharma, Olson has contributed to over $15 billion in transactions, including leading partnerships at Stoke Therapeutics and Alnylam Pharmaceuticals. He expressed...
09-30 20:05
USA Rare Earth Accelerates Mine-to-Magnet Strategy with the Transformative Acquisition of Less Common Metals (LCM)
USA Rare Earth acquires UK-based LCM for $106.7M, solidifying its leadership in rare earth production outside China. The deal enhances USAR's end-to-end supply chain, enabling sustainable rare earth alloy production and recycling capabilities. USAR secures $125M equity investment to accelerate growth. A conference call will discuss the acquisition at 8:30am ET.
09-29 10:05
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Assessing Ultragenyx Pharmaceutical: Insights From 8 Financial Analysts
In the preceding three months, 8 analysts have released ratings for Ultragenyx ...
09-05 22:01
Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $105 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains $105 price target.
09-05 21:44
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.
09-05 02:50
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
09-03 01:35
Ultragenyx to Participate at Investor Conferences in September
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced its participation in three upcoming investor conferences in September 2025. Eric Crombez, M.D., Chief Medical Officer, and Howard Horn, Chief Financial Officer, will attend the Cantor Global Healthcare Conference on September 4 in New York. Eric Crombez will also participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 and the Bank of America Global Healthcar...
08-29 20:30
Mereo BioPharma signs licensing deal with privately held āshibio
Mereo BioPharma (NASDAQ:MREO) signed an exclusive licensing deal with privately held biotech āshibio, for the antibody therapy vantictumab, intended to treat autosomal dominant osteopetrosis type 2. A...
08-19 21:43
